⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
globenewswire.com
ALLO
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
globenewswire.com
ALLO
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
globenewswire.com
ALLO
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
globenewswire.com
ALLO
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
globenewswire.com
CLLS
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
globenewswire.com
ALLO